Source: The Verge
Health hardware companies are designing products explicitly for people using weight-loss drugs like Ozempic and Wegovy, treating pharmacological users as a distinct consumer segment with specific tracking needs. This reflects how rapidly GLP-1 adoption has scaled—manufacturers now see it as a durable market category, not a temporary trend, and are building features around drug-assisted weight management rather than traditional fitness goals. The move shows how quickly consumer tech responds to medical adoption curves, though it raises questions about whether hardware built for pharmaceutical intervention adequately serves people managing weight through conventional means.